fda announcement semaglutide Big news from the last week: Wegovy (semaglutide) was approved for a new use, other than weight loss FDA sets tirzepatide compounding deadlines

Unlimited provider messaging Message your care team as often as you need between visits

Statistical significance was calculated by two-way ANOVA followed by multiple comparisons in a-d

Semaglutide binds GLP1 receptors in the brain and gut, reinforcing the satiety message sent to the hypothalamus and brainstem

Another cause could be transient shifts in B vitamins and electrolytes, which are vital for nerve health, caused by rapid weight loss and reduced food intake

Skipping meals may seem appealing when appetite is suppressed, but it can lead to blood sugar fluctuations and rebound cravings

Semaglutide is most effective when paired with a healthy diet and exercise